It compared extended-release dipyridamole plus aspirin (eDYP-ASA) versus clopidogrel and telmisartan versus antihypertensive regimens excluding angiotensin receptor blockers (ARBs)
C
Telmisartan for Prevention of Cardiovascular Events
The ProFESS study 16 compared telmisartan 80 mg daily (n = 10,146) with placebo (n = 10,186) initiated early after an ischemic stroke, less than 90 days before
This study Briefly, PRoFESS compared the effect of lowering BP with telmisartan (ARA, 80 mg daily) vs placebo, and combined aspirin (25 mg twice daily) and extended release dipyridamole (200 mg twice daily) vs
Telmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater? Stroke
541276
Mean blood pressure was lower in the telmisartan group than in the placebo group throughout the study (weighted mean difference between groups 4
It is of interest to evaluate the clinical characteristics, treatment patterns, clinical effectiveness, and safety of telmisartan as a monotherapy or as part of
Telmisartan at 80 mg daily was compared with placebo in 20 392 patients with prior ischemic stroke
2% and 39
10)
efficacy of lowering blood pressure with telmisartan (on top of standard poststroke antihypertensive treatment) in patients with acute ischemic stroke
3), treatment with telmisartan 80 mg once daily initiated soon after an ischaemic stroke and continued for a mean of 2
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study Mark: This is a randomized study of 20,332 patients; 10,146 were randomized to receive telmisartan, and the rest to receive placebo
diarrhea
Salim Yusuf, Hans-Christoph Diener, Ralph L Sacco, Daniel Cotton, Stephanie Ounpuu, William A Lawton, Yuko Palesch, Cam VanderMaelen, Thor Voigt, Michael Weber, Byung-Woo Yoon, PRoFESS Study Group, Request PDF | On Jan 1, 2008, Antonio Carolei and others published YUSUF S
The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
The Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Study 29 of more than 20, 000 patients, compared the effect of telmisartan 80 mg daily with placebo in the secondary prevention of cardiovascular events including a further stroke
26 BP decreased more sharply in the telmisartan group than in the valsartan group (–24
05)
6 In LIFE,5 the advantage of losartan over atenolol in stroke prevention may have been due to the shortcoming of the -blocker7 rather than any speculated advantage of the angiotensin receptor blocker
We used a two-by-two factorial design to compare four regimens: a combination of acetylsalicylic acid (aspirin) and extended-release dipyridamole, as
Annual Report